Oxycodon/Naloxon Stada (Naloxone, Oxycodone)

Naloxone, the active ingredient in Oxycodon/Naloxon Stada, is a combination opioid analgesic presented as a fixed‑dose oral formulation for oral use. It is employed in the management of moderate to severe pain where opioid treatment is required and aims to reduce the risk of opioid‑induced respiratory depression. GNH USA supplies Oxycodon/Naloxon Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxycodon/Naloxon Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone/Naloxone is indicated for pain management in conditions that require strong opioid therapy while mitigating opioid‑induced constipation.

- Chronic cancer pain: provides sustained analgesia while reducing constipation risk. - Post‑operative pain: delivers effective postoperative analgesia with a lower incidence of bowel dysfunction. - Severe non‑cancer chronic pain: offers long‑term pain control with built‑in opioid‑antagonist protection against gastrointestinal side effects. - Acute severe pain episodes: supplies rapid, potent relief when high‑dose opioid therapy is indicated. - Palliative care pain: ensures comfort in end‑of‑life settings while minimizing opioid‑related bowel complications.

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements, though less frequent than with oxycodone alone. - Dizziness: light‑headed sensation, especially on standing. - Headache: transient cranial discomfort. - Dry mouth: reduced salivation. - Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure. - Hepatotoxicity: liver enzyme elevations or injury. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Opioid withdrawal: signs of dependence reversal if naloxone effect becomes systemic. - Seizures: rare convulsive episodes.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

- Assess renal and hepatic function: adjust use if impairment is present. - Evaluate for bowel obstruction: avoid if risk of gastrointestinal blockage exists. - Monitor for signs of opioid dependence: watch for misuse or addiction behaviors. - Caution in the elderly: increased sensitivity to central nervous system effects. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal risk. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Oxycodone/Naloxone may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may potentiate respiratory depression. - MAO inhibitors: can increase serotonergic effects and risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise oxy‑levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce analgesic efficacy. - Anticholinergic agents: may exacerbate constipation despite naloxone component. - Diuretics: can intensify hypotensive effects. - Alcohol: additive central nervous system depression.